Explore 3 Stock Ideas & Industry Insights Download Free Report

Company price
115.6 USD 0.00(0%)
Last update at 2026-11-17T21:00:00Z
VOLUME
200
Market Cap
12944.56M
P/E
19.02

Momentum Score

…

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. It offers pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Quetiapine products for antipsychotic; Trexan for rheumatoid arthritis and cancer; Easyhaler product portfolio for asthma and COPD; and Dexdor, Precedex, and Dexmedetomidine products for human use. The company also provides Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, it offers veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells drugs and products manufactured by other companies. Additionally, the company provides self-care products, including non-prescription medicines, cosmetics, dietary supplements, vitamins, and skincare products. It also offers its products online. The company has a licensing agreement with Tenax Therapeutics, Inc. to develop oral levosimendan (TNX-103) for pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF); and Bayer for the development and commercialisation of darolutamide Nubeqa. Orion Oyj was founded in 1917 and is headquartered in Espo, Finland.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
114.50
Low
115.60
High
52 Week Price Range
77.23
Low
92.05
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
115.60
Dividend Yield
1.96%
Revenue TTM
2057.80M
Revenue Per Share
14.62
Gross Profit TTM
1356.80M
Debt / Equity
0.24
ROE
53.65%
Net Debt
144.39M
ROCE
43.10%
Diluted EPS TTM
4.84

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 627.80M 413.10M 271.90M 440.30M 242.30M
Net income 500.30M 329.90M 216.80M 349.50M 193.80M
Selling general administrative 86.80M 81.70M 74.80M 279.10M 238.90M
Selling and marketing expenses 289.50M 278.10M 224.80M - -
Gross profit 1213.00M 946.40M 657.70M 849.00M 593.50M
Reconciled depreciation 56.70M 92.80M 51.50M 47.50M 45.80M
Ebit 624.77M 420.70M 277.10M 438.90M 240.30M
Ebitda 681.04M 513.50M 328.60M 489.30M 289.10M
Depreciation and amortization 56.28M 92.80M 51.50M - -
Operating income 629.00M 416.60M 274.90M 436.40M 237.70M
Other operating expenses 1257.90M 1125.80M 914.70M 4.50M 2.80M
Interest expense 8.20M 7.60M 5.20M 1.50M 1.00M
Tax provision 127.50M 83.20M 55.10M 90.80M 48.50M
Interest income 4.60M 4.60M 2.90M 1.00M 0.10M
Net interest income -4.00M -3.80M -2.80M -0.80M -1.20M
Income tax expense 127.50M 83.20M 55.10M 90.80M 48.50M
Total revenue 1889.50M 1542.40M 1189.60M 1340.70M 1041.00M
Total operating expenses 581.40M 529.80M 382.80M 904.30M 803.30M
Cost of revenue 676.50M 596.00M 531.90M 491.70M 447.50M
Total other income expense net -1.20M -3.50M -3.00M - -
Net income from continuing ops 500.30M 329.90M 216.80M 349.50M 193.80M
Net income applicable to common shares - - - 349.50M 193.80M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 2009.90M 1629.10M 1438.60M 1503.60M 1114.00M
Intangible assets 100.30M 87.90M 112.90M 103.70M 55.50M
Other current assets 0.90M 15.60M 55.60M 0.20M 0.20M
Total liab 725.40M 624.10M 548.50M 595.50M 366.10M
Total stockholder equity 1284.50M 1005.00M 890.10M 908.10M 747.90M
Other current liab 194.80M 147.00M 120.20M 31.80M 36.20M
Common stock 92.20M 92.20M 92.20M 92.20M 92.20M
Capital stock 92.20M 92.20M 92.20M 92.20M 92.20M
Retained earnings 1192.60M 922.10M 813.30M 822.90M 680.80M
Other liab - - - 123.30M 52.20M
Good will 87.20M 87.20M 87.20M 87.20M 13.50M
Other assets - 0.10M -0.30M 121.40M 53.30M
Cash 160.90M 205.60M 106.70M 332.60M 216.70M
Total current liabilities 560.30M 273.70M 264.80M 275.40M 209.20M
Current deferred revenue - - 1.10M - -
Net debt 144.39M 121.70M 93.30M - -
Short term debt 190.00M 30.10M 29.00M - -
Short long term debt 184.80M 25.70M 25.70M 13.80M -
Short long term debt total 305.29M 327.30M 200.00M - -
Other stockholder equity -0.30M -24.80M -12.10M 27.80M -6.90M
Property plant equipment - - - 312.20M 301.10M
Total current assets 1344.40M 1016.20M 825.30M 878.70M 690.30M
Net tangible assets - - - 717.10M 678.90M
Short term investments - - -7.80M - -
Net receivables 726.30M 376.40M 296.80M 196.70M 187.50M
Long term debt 105.90M 290.70M 166.30M 192.00M 100.00M
Inventory 456.30M 418.60M 362.20M 315.60M 265.20M
Accounts payable 123.50M 87.10M 102.30M 114.40M 89.60M
Accumulated other comprehensive income - 15.50M 12.60M - -
Non currrent assets other 15.20M 11.80M 76.30M - -0.20M
Non current assets total 665.50M 612.80M 613.30M 624.90M 423.70M
Capital lease obligations 14.60M 10.90M 8.10M 8.10M 8.50M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -85.20M -115.70M -154.30M -80.20M
Change to liabilities - - - -31.90M -7.70M
Total cashflows from investing activities -98.60M -85.20M -108.40M -154.30M -80.20M
Net borrowings -25.70M 124.30M -13.90M 69.40M -3.60M
Total cash from financing activities -263.60M -108.80M -243.20M -159.80M -214.80M
Net income 500.30M 413.10M 216.80M 349.50M 193.80M
Change in cash -44.70M 98.90M -225.90M 115.90M -77.70M
Begin period cash flow 205.60M 106.70M 332.60M 216.70M 294.40M
End period cash flow 160.90M 205.60M 106.70M 332.60M 216.70M
Total cash from operating activities 316.80M 293.40M 119.00M 434.40M 215.70M
Depreciation 56.70M 92.80M 51.50M 47.50M 45.20M
Other cashflows from investing activities -21.20M -22.90M -42.70M -0.10M 0.10M
Dividends paid 231.10M 228.00M 224.90M 211.20M 211.20M
Change to inventory -38.00M -56.40M -47.90M -4.10M -6.90M
Change to account receivables -336.50M -35.80M -89.00M 11.00M -21.70M
Sale purchase of stock - 0.00M 0.00M -17.90M -
Other cashflows from financing activities -6.80M -5.10M 0.10M -0.10M -0.10M
Change to netincome - - - 62.40M 13.00M
Capital expenditures 97.60M 86.90M 116.80M 56.50M 47.00M
Change in working capital -297.50M -71.30M -144.80M -25.00M -36.30M
Stock based compensation - - 12.20M - -
Other non cash items 57.30M -48.40M -16.70M 62.90M 2.40M
Free cash flow 219.20M 206.50M 2.20M 361.30M 130.70M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - General

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ORINF
Orion Oyj
-
-%
115.60 19.02 27.78 6.29 8.80 5.42 14.97
LLY
Eli Lilly and Company
-21.29
1.50%
1394.26 38.16 24.15 12.72 29.95 13.31 25.43
JNJ
Johnson & Johnson
-3.08
1.10%
275.62 30.96 20.79 6.58 7.55 6.84 19.73
ABBV
AbbVie Inc
-4.77
1.63%
288.05 74.10 16.21 7.22 50.46 8.18 27.04
RHHVF
Roche Holding AG Participation
7.51
1.59%
480.00 24.16 16.53 5.71 8.88 4.94 14.76

Profile*

Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. It offers pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Quetiapine products for antipsychotic; Trexan for rheumatoid arthritis and cancer; Easyhaler product portfolio for asthma and COPD; and Dexdor, Precedex, and Dexmedetomidine products for human use. The company also provides Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, it offers veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells drugs and products manufactured by other companies. Additionally, the company provides self-care products, including non-prescription medicines, cosmetics, dietary supplements, vitamins, and skincare products. It also offers its products online. The company has a licensing agreement with Tenax Therapeutics, Inc. to develop oral levosimendan (TNX-103) for pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF); and Bayer for the development and commercialisation of darolutamide Nubeqa. Orion Oyj was founded in 1917 and is headquartered in Espo, Finland.

Orionintie 1A, Espo, Finland, 02200

358 10 4261

4000

Name Title Year Born
Mr. Timo Lappalainen Advisor 1962
Dr. Liisa Hurme Pres, CEO & Chairman of Exec. Management Board 1967
Mr. Jari Karlson M.Sc., M.Sc. (Econ.) CFO, Sr. VP of Animal Health & Member of the Exec. Management Board 1961
Mr. Olli Huotari Ll.M. Sr. VP of Corp. Functions, Gen. Counsel, Sec. & Member of Exec. Management Board 1966
Ms. Satu Ahomäki M.Sc., M.Sc. (Econ.) Sr. VP of Commercial Operations & Member of the Exe. Mgmt. Board 1966
Ms. Virve Laitinen M.Sc. (Tech.), MBA Sr. VP of Specialty Products & Member of Exec. Management Board 1972
Prof. Outi Vaarala M.D., Ph.D. Sr. VP for R&D and Member of Exec. Management Board 1962
Mr. Juhani Kankaanpaa Sr. VP of Global Operations & Member of Exec. Management Board NA
Mr. Tuukka Hirvonen M.Sc.(Soc.) Investor Relations & Financial Communications Officer NA
Ms. Terhi Ormio VP of Communications NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…